港股異動 | 雍禾醫療(2279.HK)大漲逾11% 成功納入恆生綜指 揭開價值發現新序章
格隆匯2月23日丨“植髮第一股”雍禾醫療(2279.HK)尾盤漲幅擴大至超11%,報12.6港元,暫成交1238萬港元,總市值66.4億港元。2月18日,恆生指數公司宣佈了檢討結果。雍禾醫療等29只個股加入恆生綜合指數名單,調整將於2022年3月7日(星期一)開始生效。公司獲納入恆生綜合指數成份股,意味着其將被確認為香港股市具備代表性的優質資產之一。上市後,公司持續受到市場廣泛關注。相比眼科、牙科、整形醫美、輔助生殖等業態,雍禾醫療所在的毛髮醫療賽道增速更快。再者,港股通主要隨着恆生綜合指數成分股的調整而調整,預計雍禾醫療將正式納入港股通。若納入港股通,公司將吸引南下資金,並獲得更好的流動性。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.